Our Legacy in Thrombotic Diseases
Daiichi Sankyo has been a pioneer in the field of thrombotic diseases for more than half a century. This commitment is reflected in two antithrombotic products currently available for patients, one antiplatelet and one anticoagulant, licensed for four indications:
Efient® (prasugrel), a once-daily oral treatment which targets platelet aggregation in arteries, helps to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
LIXIANA® (edoxaban), a once-daily oral, direct factor Xa inhibitor is for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.